Recently, we developed hybrid eumelanin–silver NPs (MelaSil_Ag) with photoacoustic properties [23], functionalised with human serum albumin (HSA), targeting breast cancer cells via HSA–SPARC interaction [24], to design DOX carriers (MelaSil_Ag-HSA@DOX NPs) for BC treatment. This evidence concerns the gene SPARC and breast cancer.